ZYDUS WELLNESS LTD.-$ - 531335 - Closure of Trading Window
Intimation of Trading Window Closure27-09-2023
27-09-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201526-09-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201522-09-2023
Zydus Lifesciences gains on USFDA's final approval for skin-care topical
We have received final approval from the USFDA for Clindamycin Phosphate Gel USP. Clindamycin is an antibiotic which works by stopping the growth of bacteria and helps to decrease the number of acne lesions," Zydus Lifesciences said in a regulatory filing at the exchanges.21-09-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201513-09-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Update On Writ Petition Filed Against Union Of India And Others In The Hon'Ble High Court Of Sikkim
Update on Judgement of Hon''ble High Court of Sikkim12-09-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201511-09-2023
Zydus Lifescience receives USFDA approval for Erythromycin
The shares were down by 1.86 per cent to 613 at 01.40 pm on the BSE01-09-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201526-08-2023